About Us
Message from CEO
Our Mission
Company Profile
Management Team
History
Clinical Development
Ongoing Clinical Studies
MN-166 (Ibudilast)
About MN-166 (Ibudilast)
ALS
Oncology / Glioblastoma
DCM
CIPN
ARDS / Lung Injury
MN-001 (Tipelukast)
About MN-001（Tipelukast)
NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
Investor Relations
Press Release
Event
Media Archive
Annual Report
SEC filing
Stock Quote -TSE
Stock Quote -Nasdaq
Historical Price Lookup
Investment Calculator
Analyst Coverage
Corporate Governance
Information Request
Presentation
Corporate Presentation & Resarch Reports
MN-166 Presentation
Progressive Multiple Sclerosis (Progressive MS)
Amyotrophic Lateral Sclerosis (ALS)
Oncology / Glioblastoma
Substance Dependence and Addiction
MN-166 (ibudilast) News Articles
MN-166 (ibudilast) Publications
MN-001 Presentation
Contact Us
Contact Us
Japanese site
About Us
Message from CEO
Our Mission
Company Profile
Management Team
History
Clinical Development
Ongoing Clinical Trial
MN-166 (Ibudilast)
About MN-166 (Ibudilast)
ALS
Oncology / Glioblastoma
DCM
CIPN
ARDS / Lung Injury
MN-001 ( tipelukast)
About MN-001（Tipelukast)
NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
Investor Relations
Press Release
Event
Media Archive
Annual Report
SEC filing
Stock Quote -TSE
Stock Quote -Nasdaq
Historical Price Lookup
Investment Calculator
Analyst Coverage
Corporate Governance
Information Request
Presentation
Corporate Presentation and Equity Research Analyst Reports
MN-166 Presentation
Progressive Multiple Sclerosis (Progressive MS)
Amyotrophic Lateral Sclerosis (ALS)
Oncology / Glioblastoma
Substance Dependence and Addiction
MN-166 (ibudilast) News Articles
MN-166 (ibudilast) Publications
MN-001 Presentation
Contact Us
臨床治験データの事後解析に関する東京理科大学との共同研究契約締結のお知らせ
joint research
2018.08.22
2019.07.22
米国国立アルコール摂取障害・依存症研究所（National Institute of Alcohol Abuse and Alcoholism, NIAAA）からのR01研究助成金授与のお知らせ ～MN-166のアルコール摂取障害を対象とするフェーズ2b臨床治験～
MN-166の進行型多発性硬化症（SPRINT-MS）フェーズ2b臨床治験結果の New England Journal of Medicine への論文掲載のお知らせ
Menus
About Us
Message from CEO
Our Mission
Company Profile
Management Team
History
Clinical Development
Ongoing Clinical Trial
MN-166 (Ibudilast)
About MN-166 (Ibudilast)
ALS
Oncology / Glioblastoma
DCM
CIPN
ARDS / Lung Injury
MN-001 ( tipelukast)
About MN-001（Tipelukast)
NAFLD, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
Investor Relations
Press Release
Event
Media Archive
Annual Report
SEC filing
Stock Quote -TSE
Stock Quote -Nasdaq
Historical Price Lookup
Investment Calculator
Analyst Coverage
Corporate Governance
Information Request
Presentation
Corporate Presentation and Equity Research Analyst Reports
MN-166 Presentation
Progressive Multiple Sclerosis (Progressive MS)
Amyotrophic Lateral Sclerosis (ALS)
Oncology / Glioblastoma
Substance Dependence and Addiction
MN-166 (ibudilast) News Articles
MN-166 (ibudilast) Publications
MN-001 Presentation
Contact Us
Search
joint research
joint research
joint research
